ASTL and pancreatic neoplasm: Further, we validated SAS1B as a therapeutic target by determining that co-incubation of pancreatic cancer cell lines with anti-SAS1B ADC results in cytotoxicity in vitro, indicating that SAS1B has characteristics of a bone fide targetable antigen for pancreatic cancer.